GlassScriptPhysician profile
Warren M Sobol
NPI 1881691327
$4,870.19
in general payments reported to CMS, 2019-2025
19 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $248 · 2021: $332 · 2022: $2,590 · 2023: $509 · 2024: $543 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $2,603.89 | 2019-2023 | Yutiq, Iluvien |
| Regeneron Healthcare Solutions, INC. | $352.25 | 2019-2025 | Eylea, Eylea Hd |
| Apellis Pharmaceuticals, INC. | $261.02 | 2023-2025 | Syfovre |
| Genentech USA, INC. | $241.39 | 2022-2025 | Vabysmo, Susvimo |
| Eyepoint US, INC. | $234.47 | 2021-2022 | |
| Sandoz INC. | $208.00 | 2024 | Cimerli |
| Abbvie INC. | $166.20 | 2022-2025 | |
| Coherus Oncology, INC. | $155.92 | 2023 | |
| Mallinckrodt Hospital Products INC. | $127.10 | 2025 | Acthar |
| Allergan, INC. | $119.04 | 2020-2021 | |
| Astellas Pharma US INC | $105.46 | 2023-2025 | Izervay |
| Amgen INC. | $79.36 | 2025 | Tepezza |
| Regeneron Pharmaceuticals, INC. | $46.86 | 2019 | |
| Halozyme INC | $45.12 | 2024 | Hylenex Recombinant |
| Harrow Eye, LLC | $31.78 | 2025 | Triesence |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $28.65 | 2019 | |
| Spark Therapeutics, INC. | $24.08 | 2020 | |
| Bausch & Lomb Americas INC. | $20.99 | 2022 | |
| Ani Pharmaceuticals, INC. | $18.61 | 2025 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Sobol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.